Discover and read the best of Twitter Threads about #HCC

Most recents (5)

#tweetorial 🧵
🚩AL & MM - Transcriptional patterns link common causal root with differing behaviours
➡️Light-chain amyloidosis (AL) and multiple myeloma (MM), are plasma cell (PC) malignancies with strikingly different clinical presentations 🥼🩺
➡️Success in🎯identifying these mechanisms has thus far been limited 👎
➡️Alameda et al define a “transcriptional atlas” of normal PCs, AL amyloidosis, MM, and MGUS, identifying 13 different transcriptional patterns linking distinct PC dyscrasias to subsets of normal developing PCs, with diagnostic 🔬and prognostic implications
Read 19 tweets
#climat #5G #HCC
1/12 Le @hc_climat à sorti son rapport sur l'impact environnemental de la #5G.
Et c'est plutôt bien foutu et intéressant. 5 scénarios sont établis :
- 3 de développement de la 5G (haute, intermédiaire et basse)
- 2 de non déploiement (haut et bas). Image
2/12 On constate aussi que les 3/4 des émissions de GES lié à la 5G sont dû au travail en amont (fabrication des terminaux, mise en place du réseau et construction des datacenters) et que l'utilisation en elle même compte pour 1/4. Image
3/12 Le @hc_climat regrette que le déploiement ait été initié antérieurement aux analyse d'impacts climatique et conseil qu'à l'avenir, ces démarches soient effectués en amont.
Read 13 tweets
Bird’s-eye view 👁 on what to look out for @WCGIC #WorldGI2020.
Opening remarks on important data 📺 @myESMO - by Dr. Eric Van Cutsem @UZLeuven.
🟩Good to see more #PrecisionMedicine🧬
🟥#Immunotherapy #Immuno-#oncology
🟦TNT & other chemo strategies
@Annals_Oncology #OncoAlert
🆕#ctDNA #liquidbiopsies 🩸🧬
👀 👇🏾at the number of #clinicaltrials cropping up in this space‼️
We have 2🇺🇸studies open. #CRCSM #WorldGI2020
#WORLDGI2020 This is 🆒 ☢️ 32-P EUS-guided implantation in #pancreascancer #PANCSM @myESMO @WCGIC @Annals_Oncology.

Still miles to go. OS median of 16 months pointing again to the systemic nature of disease. Need to piggyback these local approaches to better systemic. #OncoAlert
Read 55 tweets
For #GIJournalClub – we will discussing the @NEJM article:
Atezolizumab + Bevacizumab in Unresectable HCC (IMbrave150 trial) by Dr. Richard Finn et al.
Expert opinion: @SeragHashem
Moderators: @AtoosaRabiee @jturnesv…

#livertwitter #GIJC #hpbcsm
✅ Sorafenib in 2008: improved OS + longer time to radiologic progression vs placebo…

Single agent PD-L1 inhibitor w/o improved OS
✅ Nivoumab vs sorafenib: No statistically significant improvement in OS w/nivolumab…
Background – drug mechanisms:
- Atezolizumab: a programmed death ligand 1 (PD-L1) inhibitor
- Bevacizumab: a monoclonal antibody targeting the VEGF
- Sorafenib: multikinase inhibitor

[Picture credit:…]
Read 15 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!